RT Journal Article SR Electronic T1 Effect of a widespread reduction in treatment duration for group A streptococcal pharyngitis on outcomes and household transmission JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.10.09.24315208 DO 10.1101/2024.10.09.24315208 A1 Bloomfield, Max A1 Reed, Hamish A1 Todd, Sue A1 van der Werff, Koen A1 Balm, Michelle A1 Blackmore, Tim YR 2024 UL http://medrxiv.org/content/early/2024/10/10/2024.10.09.24315208.abstract AB Background the optimal treatment duration for group A streptococcal pharyngitis (GAS-P) is debated. Shorter courses appear inferior for pharyngeal GAS eradication, however the effect of this on household transmission is uncertain. In 2022 a laboratory reporting change drove reduced treatment durations for GAS-P in our region. This study sought to assess the effect of this on outcomes.Methods positive throat swab cultures (TSC) for GAS from two years pre-change until 21 months post-change were matched to antibiotic dispensing data. Logistic models were fitted to examine associations between treatment duration and 30-day repeat antibiotic treatment, repeat GAS-positive TSC, and hospitalisation with complications; 90-day incidence of rheumatic fever; 30-day incident household GAS-P cases.Results 865 patients pre-change and 1604 post-change were included. Pre-change 32.8% received ≤7 days treatment, versus 60.0% post-change (p<0.01). There were no significant differences across any outcome measure at a population level between periods. When the post-change period was examined specifically, no significant differences occurred for any outcome measure for patients receiving five- or seven-days of antibiotics versus ten-days. Patients receiving no antibiotics also had similar outcomes, except for significantly higher odds of 30-day household cases (aOR 2.93, 95%-CI 1.44-5.96, p<0.01).Conclusions shorter treatment durations driven by a change in laboratory reporting resulted in no detectable change in GAS-P outcomes, except for more common household transmission in those receiving no treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New Zealand Health and Disability Ethics Committees waived ethical approval for this work (2024 OOS 21470).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.